Merck, known as MSD outside the United States and Canada, has started the submission of a rolling Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for V920 (rVSV?G-ZEBOV-GP, live attenuated), the company’s investigational vaccine for Ebola Zaire disease. This rolling submission is made pursuant to the FDA’s Breakthrough Therapy Designation for V920, which was announced by the company in July 2016.
